Making a difference with your help.
Protocol Name: A Phase 3, Randomized, Double-Blind,Placebo-Controlled Study of Povetacicept in Adults with IgA Nephropathy (Rainier) Sponsor: Alpine Immune Sciences / Vertex Indication: IgA Nephropathy GFR: ≥30 DETAILS >
Protocol Name: Study of Efficacy and Safety of Iptacopan in Participants With Active Lupus Nephritis Class III-IV, +/- V Sponsor: Novartis Indication: Lupus Nephritis GFR: ≥ 25 DETAILS >
Protocol Name: Observational Study Protocol – Fabry Disease Registry Sponsor: Sanofi-Aventis Indication: Fabry Disease Principal Investigator: Ankit Mehta, MD Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204 DETAILS >
Observational Study Protocol – Fabry Disease Registry Read More »
Protocol Name: A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Subjects With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Sponsor: AMG 20220159 A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Subjects With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Indication: Antineutrophil Cytoplasmic
A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis Read More »
Protocol Name: ACTION3: A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB Sponsor: Dimerix B Indication: FSGS GFR: > 30 Primary Investigator: Kim Rice, MD Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204 DETAILS >